All lobbying filings

TODD STRATEGY GROUP

Lobbying for NOVARTIS, INC. · â€‹Multinational biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 6

HR 5376
Impacts and Outcomes for Health Career Training Act
HR 1672
Maintaining Investments in New Innovation Act
S 3131
USS Frank E. Evans Act
HR 5539
POW Priority Care Act of 2025
S 832
EPIC Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 3

Health Issues

Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.

Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.

Trade (domestic/foreign)

Tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.